6-(6-Methyl-pyridin-2-ylethynyl)-quinoxaline | 442517-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-(6-Methyl-pyridin-2-ylethynyl)-quinoxaline
• 英文别名: 6-((6-Methylpyridin-2-yl)ethynyl)quinoxaline；6-[2-(6-methylpyridin-2-yl)ethynyl]quinoxaline
• CAS: 442517-35-3
• 化学式: C₁₆H₁₁N₃
• 分子量: 245.283
• InChiKey: FJXBNXTYPDZJFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(6-Methyl-pyridin-2-ylethynyl)-quinoxaline 在 叠氮基三甲基硅烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 以68%的产率得到6-[5-(6-Methyl-pyridin-2-yl)-2H-[1,2,3]triazol-4-yl]-quinoxaline
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.024
• 作为产物：
  描述：

  2-溴-6-甲基吡啶 、 6-乙炔喹噁啉 在 copper(l) iodide 、 四(三苯基膦)钯 、 四甲基乙二胺 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 以80%的产率得到6-(6-Methyl-pyridin-2-ylethynyl)-quinoxaline
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.024

文献信息

• [EN] USE OF IMIDAZOLYL CYCLIC ACETAL DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES MEDIATED BY THE ALK5 RECEPTORS<br/>[FR] UTILISATION DE DERIVES D'ACETALS D'IMIDAZOLYLE CYCLIQUES DANS LA FABRICATION D'UN MEDICAMENT POUR LE TRAITEMENT DE MALADIES INDUITES PAR LES RECEPTEURS D'ALK5
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2002055077A1

  公开（公告）日：2002-07-18

  The use of imidazolyl-cyclic acetals as inhibitors of the tranforming growth factor, ('TGF')-βbeta signaling pathway, in particular, the phosphorylation of smad2 or smad3 bz the type I or activinlike kinase (ALK')-5 receptor are disclosed.
• Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor
  作者：Dae-Kee Kim、Joonseop Kim、Hyun-Ju Park

  DOI：10.1016/j.bmcl.2004.03.024

  日期：2004.5

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.